Ribavirin Peginterferon alfa

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales EL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 975-982... [Pg.233]

Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40(6) 993-999... [Pg.346]

Zeuzem S, Buti M, Ferenci P, Sped J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, NovieUo S, Brass C, Albrecht J (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1) 97-103... [Pg.346]

The safety and efficacy of ribavirin capsules or oral solution with interferons other than interferon alfa-2b or peginterferon alfa-2b products have not been established. [Pg.1772]

Peginterferon alfa-2a and Ribavirin Tabiet Dosing Recommendations... [Pg.1772]

Ribavirin capsuies/Peginterferon alfa-2b combination therapy (adults) - The recommended dose of ribavirin capsules is 800 mg/day in 2 divided doses 2 capsules (400 mg) in the morning with food and 2 capsules (400 mg) in the evening with food. [Pg.1775]

Ribavirin tablets/Peginterferon alfa-2a Ribavirin tablets/peginterferon alfa-2a combination therapy is contraindicated in patients with autoimmune hepatitis and... [Pg.1777]

Capsules/Tablets/Oral solution - Ribavirin monotherapy is not effective for the treatment of chronic HCV infection. The safety and efficacy of ribavirin capsules and oral solution have only been established when used together with interferon alfa-2b, recombinant as interferon alfa-2b/ribavirin capsule combination therapy or with peginterferon alfa-2b injection. [Pg.1778]

Capsules/Tablets/Oral solution-There are significant adverse events caused by ribavirin capsules/interferon alfa-2b or peginterferon alfa-2b therapy, and ribavirin tablets/peginterferon alfa-2a therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. [Pg.1778]

Pancreatitis Suspend ribavirin, interferon alfa-2b, peginterferon alfa-2b, or peginterferon alfa-2a therapy in patients with signs and symptoms of pancreatitis and discontinue in patients with confirmed pancreatitis. [Pg.1779]

Capsules/Oral solution - Suicidal ideation or attempts occurred more frequently among pediatric patients, primarily adolescents, compared with adult patients during treatment and off-therapy follow-up. Safety and efficacy of ribavirin in combination with peginterferon alfa-2b has not been established in pediatric patients. [Pg.1781]

Peginterferon alfa-2a/Ribavirin tablet combination The recommended dose of peginterferon alfa-2a when used in combination with ribavirin tablets is 180 meg (1 mL vial or 0.5 mL prefilled syringe) subcutaneously once weekly. The recommended dose of ribavirin and duration for the peginterferon alfa-2a/ribavirin tablet combination therapy is based on viral genotype. [Pg.1981]

Combination therapy with ribavirin tabiets-The recommended dose when used in combination with ribavirin tablets is peginterferon alfa-2a 180 meg subcutaneously once weekly and oral ribavirin tablets 800 mg daily given in 2 divided doses for a total of 48 weeks, regardless of genotype. Because ribavirin absorption increases when administered with a meal, patients are advised to take ribavirin with food. [Pg.1984]

Renal function impairment- In patients with end-stage renal disease requiring hemodialysis, dose reduction to 135 meg peginterferon alfa-2a is recommended. Closely monitor for signs and symptoms of interferon toxicity. Do not use ribavirin in patients with creatinine clearance less than 50 mL/min. [Pg.1987]

Bone marrow toxicity Peginterferon alfa-2a suppresses bone marrow function and may result in severe cytopenias. Ribavirin may potentiate the neutropenia and lymphopenia induced by alpha interferons including peginterferon alfa-2a. Alpha interferons may be associated with aplastic anemia very rarely. [Pg.1989]

Lactation It is not known whether peginterferon alfa-2a or ribavirin or its components are excreted in breast milk. [Pg.1991]

Immunogenicity Nine percent of patients treated with peginterferon alfa-2a with or without ribavirin tablets developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. The clinical and pathological significance of the appearance of serum neutralizing antibodies is unknown. [Pg.1991]

Safety and efficacy The safety and efficacy of peginterferon alfa-2a alone or in combination with ribavirin tablets have not been established for the treatment of chronic hepatitis C in patients who are ... [Pg.1991]

Peginterferon alfa-2a dose was reduced in 12% of patients receiving 1,000 to 1,200 mg ribavirin tablets for 48 weeks and in 7% of patients receiving 800 mg ribavirin tablets for 24 weeks. Ribavirin tablet dose was reduced in 21% of patients receiving 1,000 to 1,200 mg ribavirin tablets for 48 weeks and 12% in patients receiving 800 mg ribavirin tablets for 24 weeks. [Pg.1992]

Peginterferon alfa-2b/Ribavirin capsules combination therapy V lhen administered in combination with ribavirin capsules, the recommended dose of peginterferon alfa-2b is 1.5 mcg/kg/week. The volume of peginterferon alfa-2b to be injected depends on the strength of peginterferon alfa-2b and the patient s body weight. [Pg.1994]

Discontinuation It is recommended that patients receiving peginterferon alfa-2b alone or in combination with ribavirin be discontinued from therapy if hepatitis C... [Pg.1994]

Dose reduction If a serious adverse reaction develops during the course of treatment (see Warnings, Precautions), discontinue or modify the dosage of peginterferon alfa-2b and/or ribavirin capsules until the adverse reaction abates or decreases in severity. If persistent or recurrent serious adverse reactions develop despite adequate dosage adjustment, discontinue treatment. Decreases in hemoglobin, neutrophils, and platelets may require dose reduction or permanent discontinuation from therapy. For guidelines for dose modifications and discontinuation based on laboratory parameters, see the tables below. [Pg.1995]

Guidelines for Modification or Discontinuation of Peginterferon Alfa-2b or Peginterferon Alfa-2b/Ribavirin Capsules and for Scheduling Visits for Patients... [Pg.1995]

Anemia Ribavirin caused hemolytic anemia in 10% of peginterferon alfa-2b/ribavirin capsule-treated patients within 1 to 4 weeks of initiation of therapy. Obtain complete blood counts pretreatment and at weeks 2 and 4 of therapy or more frequently if clinically indicated. [Pg.1999]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...